Show simple item record

dc.contributor.authorTamura, Manabu
dc.contributor.authorWebster, Robert G.
dc.contributor.authorEnnis, Francis A.
dc.date2022-08-11T08:09:10.000
dc.date.accessioned2022-08-23T16:19:42Z
dc.date.available2022-08-23T16:19:42Z
dc.date.issued1993-08-01
dc.date.submitted2017-11-13
dc.identifier.citationJ Immunol. 1993 Aug 1;151(3):1731-8.
dc.identifier.issn0022-1767 (Linking)
dc.identifier.pmid7687637
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35114
dc.description.abstractWe studied 18 mAb specific for the H3 hemagglutinin (HA) to analyze the relationships between neutralizing and infection-enhancing epitopes on the influenza HA. The mAb could be separated into three groups based on their neutralization (N) and enhancement (E) activity in assays with the prototype virus; group I (N+E+), group II (N+E-) and group III (N +/- E+). A representative mAb from each group was analyzed for its effect on the infectivity of a group of escape mutants, selected with mAb to three sites on the H3 HA, and wild-type H3 viruses to define the relationship between neutralizing epitopes and infection-enhancing epitopes. A group I mAb (N+E+), which recognized site A on the HA, neutralized virus infection at high concentrations of antibody and enhanced virus infection at low concentrations. A group II mAb (N+E-), which recognized site B, had high neutralizing but no enhancing activity. The failure of this mAb to enhance virus uptake was a result of the inability of the Fc portion of virus-mAb complexes to bind to Fc receptor. The addition of anti-murine IgG as a second antibody to these virus-mAb complexes augmented virus uptake. A group III mAb (N +/- E+), which recognized site C, had enhancing but little neutralizing activity. This is the first definition of distinct epitopes that induce neutralizing and/or enhancing mAb.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=7687637&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.jimmunol.org/content/151/3/1731.long
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirology
dc.titleNeutralization and infection-enhancement epitopes of influenza A virus hemagglutinin
dc.typeJournal Article
dc.source.journaltitleJournal of immunology (Baltimore, Md. : 1950)
dc.source.volume151
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/323
dc.identifier.contextkey11035662
html.description.abstract<p>We studied 18 mAb specific for the H3 hemagglutinin (HA) to analyze the relationships between neutralizing and infection-enhancing epitopes on the influenza HA. The mAb could be separated into three groups based on their neutralization (N) and enhancement (E) activity in assays with the prototype virus; group I (N+E+), group II (N+E-) and group III (N +/- E+). A representative mAb from each group was analyzed for its effect on the infectivity of a group of escape mutants, selected with mAb to three sites on the H3 HA, and wild-type H3 viruses to define the relationship between neutralizing epitopes and infection-enhancing epitopes. A group I mAb (N+E+), which recognized site A on the HA, neutralized virus infection at high concentrations of antibody and enhanced virus infection at low concentrations. A group II mAb (N+E-), which recognized site B, had high neutralizing but no enhancing activity. The failure of this mAb to enhance virus uptake was a result of the inability of the Fc portion of virus-mAb complexes to bind to Fc receptor. The addition of anti-murine IgG as a second antibody to these virus-mAb complexes augmented virus uptake. A group III mAb (N +/- E+), which recognized site C, had enhancing but little neutralizing activity. This is the first definition of distinct epitopes that induce neutralizing and/or enhancing mAb.</p>
dc.identifier.submissionpathinfdis_pp/323
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.source.pages1731-8


This item appears in the following Collection(s)

Show simple item record